GGrantIndex
Sort

4,870 grants matching glp 1

GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weight

$697,726
Ania Jastreboff · Yale University · R01 · FY2021 · DK

GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weight

$697,726
Ania Jastreboff · Yale University · R01 · FY2023 · DK

GLP-1 analogue effects on food cues, stress, motivation for highly palatable foods, and weight

$697,726
Ania Jastreboff · Yale University · R01 · FY2022 · DK

Large animal therapy studies

$696,911
William A. Beltran · University Of Pennsylvania · R24 · FY2013 · EY

Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes

$696,763
David Eric Arterburn · Kaiser Foundation Research Institute · R01 · FY2024 · DK

Large animal therapy studies

$696,492
William A. Beltran · University Of Pennsylvania · R24 · FY2014 · EY

Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes

$695,237
Ming C Gong · University Of Kentucky · R01 · FY2023 · HL

Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes

$695,237
Ming C Gong · University Of Kentucky · R01 · FY2025 · HL

Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes

$695,237
Ming C Gong · University Of Kentucky · R01 · FY2022 · HL

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans with Prediabetes

$694,913
Absalon Dennis Gutierrez · University Of Texas Hlth Sci Ctr Houston · R01 · FY2023 · DK

Increased Protein at Breakfast for Weight Management in Overweight Adolescents

$694,804
Heather J Leidy · University Of Texas At Austin · R01 · FY2019 · DK

A new radiopharmaceutical for the treatment of metastatic bone cancer

$694,709
Jaime Nmn Simon · Isotherapeutics Group, Llc · R44 · FY2013 · CA

In-Situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

$694,475
Hamid Ghandehari · Theratarget · R42 · FY2017 · CA

Glycemic and Weight Loss Effects of Semaglutide in Subjects After Spinal Cord Injury and Type 2 Diabetes

$694,221
Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2025 · DK

Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer

$693,171
Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2022 · CA

Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics

$693,075
Mandar Deepak Muzumdar · Yale University · R01 · FY2025 · CA

Advancing ADPKD Treatment with GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism

$692,934
Kristen Lynn Nowak · University Of Colorado Denver · R01 · FY2024 · DK

Evaluation of the entero-insular (incretin) axis in cystic fibrosis-competitive renewal.

$692,825
Andrea Bridget Kelly · Children'S Hosp Of Philadelphia · R01 · FY2020 · DK

EP055, a non-hormonal male contraceptive:IND-enabling studies

$692,614
Michael G O'Rand · Eppin Pharma, Inc. · R44 · FY2021 · HD

The weight-independent effects of bariatric surgeries on islet cell function

$692,362
Marzieh Salehi · Cedars-Sinai Medical Center · R01 · FY2016 · DK

Reduced Carbohydrate Diet Intervention for PCOS

$692,049
Barbara A. Gower · University Of Alabama At Birmingham · R01 · FY2009 · HD

Optimizing the Safety of the Newer Diabetes Medications in Patients with Diabetes and Kidney Disease

$691,774
Julie Paik · Brigham And Women'S Hospital · R01 · FY2025 · DK

Image-guided Bariatric Arterial Embolization (BAE) for the Treatment of Obesity

$690,951
Dara L Kraitchman · Johns Hopkins University · R01 · FY2023 · DK

Effects of bimagrumab on body composition, insulin sensitivity, and bone in adults with obesity

$690,694
Melanie Schorr Haines · Massachusetts General Hospital · R01 · FY2024 · DK

Glycemic and Weight Loss Effects of Semaglutide in Subjects After Spinal Cord Injury and Type 2 Diabetes

$690,638
Marzieh Salehi · University Of Texas Hlth Science Center · R01 · FY2024 · DK